Loading...

Kura Oncology

DB:KUR
Snowflake Description

Excellent balance sheet with moderate growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
KUR
DB
$564M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The last earnings update was 48 days ago. More info.


Add to Portfolio Compare Print
KUR Share Price and Events
7 Day Returns
-3.6%
DB:KUR
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
-2.9%
DB:KUR
-10.2%
DE Biotechs
-6%
DE Market
KUR Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Kura Oncology (KUR) -3.6% -7.1% -6% -2.9% 341.9% -
DE Biotechs -2.4% 3.8% -8.6% -10.2% 51.2% 10.1%
DE Market 1.8% 6% 7.8% -6% 10.1% 15.3%
1 Year Return vs Industry and Market
  • KUR outperformed the Biotechs industry which returned -10.2% over the past year.
  • KUR outperformed the Market in Germany which returned -6% over the past year.
Price Volatility
KUR
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Kura Oncology undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Kura Oncology to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Kura Oncology.

DB:KUR Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 6 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:KUR
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.45
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.448 (1 + (1- 21%) (1.33%))
1.31
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.31
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.31 * 5.96%)
8.04%

Discounted Cash Flow Calculation for DB:KUR using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Kura Oncology is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:KUR DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 8.04%)
2019 -59.80 Analyst x2 -55.35
2020 -73.18 Analyst x3 -62.69
2021 -61.28 Analyst x2 -48.60
2022 -2.16 Analyst x2 -1.59
2023 73.71 Analyst x2 50.08
2024 87.19 Est @ 18.29% 54.84
2025 98.42 Est @ 12.87% 57.29
2026 107.36 Est @ 9.08% 57.84
2027 114.25 Est @ 6.42% 56.98
2028 119.47 Est @ 4.57% 55.15
Present value of next 10 years cash flows $163.96
DB:KUR DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $119.47 × (1 + 0.23%) ÷ (8.04% – 0.23%)
$1,533.49
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $1,533.49 ÷ (1 + 8.04%)10
$707.91
DB:KUR Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $163.96 + $707.91
$871.86
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $871.86 / 38.17
$22.84
DB:KUR Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:KUR represents 0.8682x of NasdaqGS:KURA
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.8682x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 22.84 x 0.8682
€19.83
Value per share (EUR) From above. €19.83
Current discount Discount to share price of €12.83
= -1 x (€12.83 - €19.83) / €19.83
35.3%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Kura Oncology is available for.
Intrinsic value
35%
Share price is €12.83 vs Future cash flow value of €19.83
Current Discount Checks
For Kura Oncology to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Kura Oncology's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Kura Oncology's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Kura Oncology's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Kura Oncology's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:KUR PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-1.72
NasdaqGS:KURA Share Price ** NasdaqGS (2019-04-18) in USD $14.78
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Kura Oncology.

DB:KUR PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:KURA Share Price ÷ EPS (both in USD)

= 14.78 ÷ -1.72

-8.6x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Kura Oncology is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Kura Oncology is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Kura Oncology's expected growth come at a high price?
Raw Data
DB:KUR PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -8.6x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts
21.1%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Kura Oncology, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Kura Oncology's assets?
Raw Data
DB:KUR PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $4.22
NasdaqGS:KURA Share Price * NasdaqGS (2019-04-18) in USD $14.78
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:KUR PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:KURA Share Price ÷ Book Value per Share (both in USD)

= 14.78 ÷ 4.22

3.5x

* Primary Listing of Kura Oncology.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Kura Oncology is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Kura Oncology's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Kura Oncology has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Kura Oncology expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
21.1%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Kura Oncology expected to grow at an attractive rate?
  • Kura Oncology's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Kura Oncology's earnings growth is expected to exceed the Germany market average.
  • Unable to compare Kura Oncology's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:KUR Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:KUR Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts 21.1%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:KUR Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:KUR Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 147 105 29 4
2022-12-31 72 40 -35 4
2021-12-31 27 11 -78 4
2020-12-31 0 -65 -88 5
2019-12-31 0 -64 -74 6
DB:KUR Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 -49 -60
2018-09-30 -46 -55
2018-06-30 -39 -49
2018-03-31 -33 -43
2017-12-31 -28 -35
2017-09-30 -28 -32
2017-06-30 -27 -30
2017-03-31 -27 -28
2016-12-31 -25 -28
2016-09-30 -24 -27
2016-06-30 -23 -26
2016-03-31 -21 -25

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Kura Oncology's earnings are expected to grow significantly at over 20% yearly.
  • Unable to determine if Kura Oncology is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:KUR Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below

All data from Kura Oncology Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:KUR Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 0.64 1.45 0.13 3.00
2022-12-31 -1.14 -0.26 -2.24 4.00
2021-12-31 -1.77 -0.59 -2.50 5.00
2020-12-31 -2.15 -1.72 -2.50 6.00
2019-12-31 -1.92 -1.80 -2.11 5.00
DB:KUR Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -1.72
2018-09-30 -1.67
2018-06-30 -1.67
2018-03-31 -1.61
2017-12-31 -1.52
2017-09-30 -1.55
2017-06-30 -1.53
2017-03-31 -1.50
2016-12-31 -1.47
2016-09-30 -1.50
2016-06-30 -1.64
2016-03-31 -1.81

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Kura Oncology will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Kura Oncology's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Kura Oncology has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Kura Oncology performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Kura Oncology's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Kura Oncology does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Kura Oncology's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Kura Oncology's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Kura Oncology's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Kura Oncology Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:KUR Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 -60.45 16.10 46.79
2018-09-30 -55.10 14.42 42.82
2018-06-30 -49.42 12.46 38.30
2018-03-31 -42.51 10.94 32.48
2017-12-31 -35.43 9.65 26.43
2017-09-30 -32.03 8.75 23.81
2017-06-30 -29.63 8.14 21.98
2017-03-31 -28.47 7.71 21.27
2016-12-31 -27.56 7.96 20.40
2016-09-30 -26.69 7.72 20.01
2016-06-30 -25.85 7.77 19.33
2016-03-31 -24.78 7.42 18.80
2015-12-31 -22.63 6.09 17.78
2014-12-31 -11.01 3.85 7.96

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Kura Oncology has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Kura Oncology has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Kura Oncology improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Kura Oncology's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Kura Oncology has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Kura Oncology's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Kura Oncology's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Kura Oncology is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Kura Oncology's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Kura Oncology's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 24.2x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Kura Oncology Company Filings, last reported 3 months ago.

DB:KUR Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 160.99 7.50 178.99
2018-09-30 174.61 6.27 187.42
2018-06-30 112.40 6.96 125.89
2018-03-31 124.80 7.16 138.20
2017-12-31 79.87 7.10 93.15
2017-09-30 89.20 7.04 100.81
2017-06-30 43.64 7.36 53.24
2017-03-31 50.24 7.34 59.15
2016-12-31 56.88 7.32 67.79
2016-09-30 63.67 7.31 74.57
2016-06-30 70.04 7.29 80.09
2016-03-31 76.07 0.00 78.47
2015-12-31 82.10 0.00 85.75
2014-12-31 -3.43 2.53 1.12
  • Kura Oncology's level of debt (4.7%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Kura Oncology's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Kura Oncology has sufficient cash runway for more than 3 years based on current free cash flow.
  • Kura Oncology has sufficient cash runway for 2.8 years if free cash flow continues to grow at historical rates of 29.8% each year.
X
Financial health checks
We assess Kura Oncology's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Kura Oncology has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Kura Oncology's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Kura Oncology dividends. Estimated to be 0% next year.
If you bought €2,000 of Kura Oncology shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Kura Oncology's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Kura Oncology's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:KUR Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:KUR Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Kura Oncology has not reported any payouts.
  • Unable to verify if Kura Oncology's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Kura Oncology's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Kura Oncology has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Kura Oncology's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Kura Oncology's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Kura Oncology afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Kura Oncology has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Kura Oncology's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Troy Wilson
COMPENSATION $1,721,112
AGE 49
TENURE AS CEO 4.1 years
CEO Bio

Dr. Troy Edward Wilson, Ph.D., J.D. has been the Chairman of the Board, Chief Executive Officer and President at Kura Oncology, Inc. since March 2015. He was the Chief Financial Officer and Principal Accounting Officer at Kura Oncology, Inc. since July 06, 2018. Dr. Wilson serves as the President and Chief Executive Officer of Araxes Pharma, LLC since July 2012. Dr. Wilson has been the President and Chief Executive Officer of Avidity Biosciences LLC since November 2012 and serves as its Member of Board of Managers since November 2012. He has been the President and Chief Executive Officer of Wellspring Biosciences LLC since July 2012. He serves as Senior Advisor at Ambrx, Inc. He served as a Founding Partner CMEA 8 at CMEA Capital. Dr. Wilson joined CMEA Capital in 2012. He served as a Business Advisor of Centrose LLC. He co-founded Wellspring Biosciences. He Co-Founded Intellikine, Inc. and served as its Chief Executive Officer and President from April 2007 to January 2012. He co-founded Ambrx, Inc. in 2003 and served as its Chief Business Officer. He co-founded Wildcat. He served as Vice President of Business Development and General Counsel at the Genomics Institute of the Novartis Research Foundation, where his responsibilities included oversight of all business development, licensing, legal and intellectual property functions of the Institute. He was also actively involved in the creation and launch of the Institute's three spinout companies - Kalypsys, Phenomix and Syrrx. He was associated with a law firm in New York, where he was a Member of its Corporate Finance and Technology transactions practice groups. He has also been a Member of the Board of Managers of Araxes Pharma LLC since May 2012. He has been an Independent Director of Zosano Pharma Corporation since June 20, 2014. He has been a Member of the Board of Managers at Avidity NanoMedicines LLC since November 2012. He has been a Member of the Board of at Wellspring Biosciences LLC since May 2012. He serves as a Director of Centrose, LLC. Dr. Wilson co-founded Prior Kura in August 2014 and served as the President and Chief Executive Officer of Prior Kura, as well as a member of Prior Kura’s Board of Directors, from August 2014 until the Upstream Merger in March 2015. He has been an Independent Director of Puma Biotechnology, Inc. since October 18, 2013. He has 12 years of building companies. He served as a Director of Intellikine, Inc. from August 2007 to January 2012. Dr. Wilson is the trustee of Red Fish Blue Fish Revocable Trust. Dr. Wilson holds Ph.D. in Bioorganic Chemistry and a B.A. in Biophysics from the University of California, Berkeley and J.D. from New York University.

CEO Compensation
  • Troy's compensation has increased whilst company is loss making.
  • Troy's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Kura Oncology management team in years:

2.4
Average Tenure
49
Average Age
  • The tenure for the Kura Oncology management team is about average.
Management Team

Troy Wilson

TITLE
Chairman
COMPENSATION
$2M
AGE
49
TENURE
4.1 yrs

Antonio Gualberto

TITLE
Head of Development & Chief Medical Officer
COMPENSATION
$1M
AGE
53

Marc Grasso

TITLE
CFO & Chief Business Officer
TENURE
0.7 yrs

John Farnam

TITLE
Chief Operating Officer
TENURE
0.8 yrs

Pete De Spain

TITLE
Vice President of Investor Relations & Corporate Communications

Pingda Ren

TITLE
Senior Vice President of Chemistry & Pharmaceutical Sciences
AGE
49
TENURE
4.1 yrs
Board of Directors Tenure

Average tenure and age of the Kura Oncology board of directors in years:

4
Average Tenure
52
Average Age
  • The tenure for the Kura Oncology board of directors is about average.
Board of Directors

Troy Wilson

TITLE
Chairman
COMPENSATION
$2M
AGE
49
TENURE
4.1 yrs

Robert Hoffman

TITLE
Independent Director
COMPENSATION
$115K
AGE
52
TENURE
4.1 yrs

Kevan Shokat

TITLE
Chairman of the Scientific Advisory Board

Faheem Hasnain

TITLE
Independent Director
COMPENSATION
$109K
AGE
60
TENURE
4 yrs

Thomas Malley

TITLE
Independent Director
COMPENSATION
$106K
AGE
49
TENURE
3.5 yrs

Frank McCormick

TITLE
Scientific Advisor
AGE
68

Neal Rosen

TITLE
Scientific Advisor
AGE
68

Steven Stein

TITLE
Director
COMPENSATION
$225K
AGE
51
TENURE
2.3 yrs

Azra Raza

TITLE
Clinical Advisor

Alan Houghton

TITLE
Clinical Advisor
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
10. Jan 19 Sell EcoR1 Capital, LLC Company 17. Dec 18 17. Dec 18 -26,520 €11.64 €-308,581
10. Jan 19 Buy EcoR1 Capital, LLC Company 18. Dec 18 21. Dec 18 213,888 €12.13 €2,542,586
13. Dec 18 Buy EcoR1 Capital, LLC Company 11. Dec 18 13. Dec 18 40,538 €12.25 €496,153
07. Dec 18 Buy EcoR1 Capital, LLC Company 03. Dec 18 06. Dec 18 119,906 €12.29 €1,423,093
X
Management checks
We assess Kura Oncology's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Kura Oncology has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company’s lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia. It is also developing KO-947, a small molecule inhibitor of extracellular signal related kinase used for the treatment of patients with tumors that have dysregulated activity due to mutations or other mechanisms in the mitogen-activated protein kinase pathway; and KO-539, a small molecule inhibitor of the menin-mixed lineage leukemia protein-protein interaction. The company was founded in 2014 and is headquartered in San Diego, California.

Details
Name: Kura Oncology, Inc.
KUR
Exchange: DB
Founded: 2014
$501,067,749
38,169,041
Website: http://www.kuraoncology.com
Address: Kura Oncology, Inc.
3033 Science Park Road,
Suite 220,
San Diego,
California, 92121,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS KURA New Common Stock Nasdaq Global Select US USD 16. Sep 2015
DB KUR New Common Stock Deutsche Boerse AG DE EUR 16. Sep 2015
Number of employees
Current staff
Staff numbers
45
Kura Oncology employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/22 22:24
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/11
Last earnings filing: 2019/03/05
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.